A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

• Status: Completed
• Trial end date: 2001-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection.

HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Azithromycin; Nelfinavir; Nevirapine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.

• Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry.

• Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection.

• Have MAC infection with 7 days or less of MAC treatment.

• Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry.

• Are 18 years of age or older.

Exclusion Criteria

You will not be eligible for this study if you:

• Have any active infection (except for MAC in Group 2 patients) or any cancer.

• Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3).

• Are pregnant or breast-feeding.